Welcome to our dedicated page for Connect Biopharma Holdings SEC filings (Ticker: CNTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Connect Biopharma Holdings Limited filings document regulatory disclosures for a Cayman Islands clinical-stage biopharmaceutical issuer developing rademikibart for inflammatory diseases. Recent Form 8-K reports cover operating and financial results, clinical and regulatory updates tied to rademikibart, and Regulation FD disclosures.
The filing record also includes governance and capital-structure matters, including board composition, insider purchase disclosures, material agreements, ADR-program and deposit-agreement disclosures, and the relationship between American depositary shares and ordinary shares. These filings frame the company’s emerging-growth-company status, public-company reporting obligations and risk-related clinical development disclosures.
Connect Biopharma Holdings Limited reported a larger quarterly loss as it increased investment in its lead respiratory drug candidate rademikibart and bolstered its cash balance through a private placement. For the three months ended March 31, 2026, net loss widened to $19.4 million from $10.3 million a year earlier, driven mainly by higher rademikibart-related research and development spending of $15.0 million versus $6.6 million in 2025.
The company generated $0.2 million in license and collaboration revenue from its Simcere agreement in Greater China and ended the quarter with $46.0 million in cash and cash equivalents. Operating cash outflow was $16.0 million. In March 2026, Connect raised $20.2 million in gross proceeds (estimated net $18.6 million) via a private placement of 6.13 million ordinary shares, increasing total shares outstanding to about 62.96 million as of April 30, 2026. Management believes existing cash will fund operations for at least one year from the filing date.
Connect Biopharma Holdings Limited reported first quarter 2026 results and highlighted progress on its asthma and COPD programs. For the three months ended March 31, 2026, license and collaboration revenues were $169,000, compared with none a year earlier. Research and development expense rose to $15.0 million, mainly from Phase 2 Seabreeze STAT asthma and COPD studies, while general and administrative expense was $4.7 million.
Net loss increased to $19.4 million, or ($0.34) per share, versus $10.3 million, or ($0.19), in 2025. Cash, cash equivalents and short-term investments totaled $46.0 million as of March 31, 2026, supported by a $20.2 million private placement that closed on March 31, 2026, which provided estimated net proceeds of $18.6 million. Management believes this cash should fund operations into the second half of 2027.
The company is advancing rademikibart, an antibody targeting IL‑4Rα, with Phase 2 Seabreeze STAT studies in acute exacerbations of asthma and COPD continuing as planned after an independent data monitoring committee review. Topline data from both Phase 2 studies are expected mid‑2026, and positive Phase 1 intravenous rademikibart data showed rapid and durable lung function improvements. In China, partner Simcere reported Phase 3 atopic dermatitis results with rapid, durable efficacy through 52 weeks. Connect remains eligible for up to approximately $110 million in remaining milestones and tiered royalties under its Simcere license.
Connect Biopharma Holdings Limited reported that an independent Data Monitoring Committee completed a pre-specified interim efficacy analysis for its Phase 2 Seabreeze STAT asthma and COPD trials of rademikibart with no recommendation to change sample size, so enrollment will continue as planned. The committee regularly reviews safety and indicated no safety concerns, with no treatment-related serious or severe adverse events and no discontinuations due to adverse events so far. Connect Biopharma expects topline data from both Seabreeze STAT studies in mid-2026 and plans to meet with the U.S. Food and Drug Administration to seek alignment on a Phase 3 program. Under an existing Greater China license for rademikibart, the company remains eligible for up to approximately $110 million in future milestones plus tiered royalties up to low double-digit percentages.
Connect Biopharma Holdings Ltd ownership disclosure: the filing reports that Biofortune Inc. holds 5,987,431 ordinary shares and that Wubin Pan is the beneficial owner of 6,026,813 ordinary shares of Connect Biopharma (CUSIP 207523101) as reported on 04/14/2026. The filing shows Biofortune Inc. beneficially owns 9.5% of the class while Mr. Pan beneficially owns 9.6%, reflecting shared voting and dispositive power due to Mr. Pan's sole ownership of Biofortune Inc.
Xanthopoulos Kleanthis Gabriel reported acquisition or exercise transactions in this Form 4 filing.
Connect Biopharma Holdings Ltd director Dr. Kleanthis Gabriel Xanthopoulos received a grant of 2,816 ordinary shares on March 31, 2026. These fully vested shares were taken in lieu of a portion of cash compensation for his 2026 annual board retainers for service in the first quarter of 2026. After this award, he directly holds 82,816 ordinary shares of the company.
LIU JEAN I reported acquisition or exercise transactions in this Form 4 filing.
Connect Biopharma Holdings Ltd director Jean I. Liu received a stock grant of 5,061 ordinary shares as board compensation. The shares are fully vested and were taken in lieu of cash for her 2026 annual board retainers, covering service during the first quarter of 2026.
The number of shares was calculated by dividing the applicable equity value by the average closing price of the company’s ordinary shares over the 30 consecutive trading days immediately before March 31, 2026, then rounded down to the nearest whole share. This is a routine, compensation-related equity award rather than an open‑market purchase or sale.
Connect Biopharma Holdings Ltd director-linked entity reports major share purchase. An entity associated with James Huang completed an open-market purchase of 1,160,000 Ordinary Shares at $3.45 per share. After this transaction, the filing shows 13,160,000 Ordinary Shares held indirectly. The shares are recorded under Panacea Venture Healthcare Fund II, L.P., and Huang may be deemed to share beneficial ownership but expressly disclaims such beneficial ownership.
Panacea Venture Healthcare Fund II, L.P. and affiliated entities filed an amended beneficial ownership report on Connect Biopharma Holdings, showing 13,160,000 Ordinary Shares, or 21.2% of the class, with shared voting and dispositive power.
On March 31, 2026, Panacea purchased 1,160,000 Ordinary Shares at $3.45 per share in a 6,130,000-share offering. The Issuer agreed to file a resale registration statement within 45 days of closing, and James Huang entered a 45-day lock-up restricting sales of his Ordinary Shares.
Connect Biopharma Holdings Limited provides an annual overview of its business as a clinical-stage company focused on asthma and COPD. The lead asset, rademikibart, is a next-generation antibody targeting IL‑4Rα, being developed first for acute exacerbations of asthma and COPD and then for chronic use.
Two Phase 2 trials (Seabreeze STAT ASTHMA and Seabreeze STAT COPD) are testing rademikibart plus standard of care versus placebo in patients with Type 2 inflammation, with treatment failure over 28 days as the primary endpoint. A Phase 1 IV study in stable asthma and COPD showed rapid FEV1 improvements within 15 minutes after a single 300 mg IV push, sustained to Day 29, and the drug was generally well tolerated.
The company highlights strong prior Phase 2b asthma and atopic dermatitis data, plus a Greater China license with Simcere, from which it has received $21 million upfront and $6.5 million in milestones and cost reimbursements, with up to about $110 million in potential additional milestones and tiered royalties. Key risks include heavy reliance on rademikibart, substantial future financing needs, intense biologics competition, and extensive U.S. and PRC regulatory, data security and geopolitical uncertainties.
Connect Biopharma reported 2025 full-year results showing it remains a clinical-stage company investing heavily in rademikibart. License and collaboration revenue was $64,000 for 2025, down from $26.0 million in 2024, reflecting the absence of prior-year upfront and milestone payments. Research and development expense rose to $37.8 million and general and administrative expense to $20.3 million, driving a wider net loss of $55.5 million, or $1.00 per share, compared with $15.6 million, or $0.28 per share, in 2024. Cash, cash equivalents and short-term investments were $44.3 million as of December 31, 2025. The company entered a $20.2 million private placement of 6,130,000 ordinary shares at $3.25 per share, which, together with existing cash, is expected to fund operations into the second half of 2027. Clinically, Connect reported positive Phase 1 IV rademikibart data in asthma and COPD with rapid FEV1 improvements of about 200–400 mL maintained through Day 29, alongside strong Phase 3 atopic dermatitis results from partner Simcere and ongoing Phase 2 Seabreeze STAT studies with topline data expected mid‑2026.